Skip to search formSkip to main contentSkip to account menu

ponalrestat

Known as: 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic Acid, 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-3H-phthalazin-1-ylacetic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Our recent study has demonstrated that ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in… 
1992
1992
1 The aim of the study was to examine the effects in rats of two different doses of the aldose reductase inhibitor, ponalrestat… 
Highly Cited
1991
Highly Cited
1991
Hyperglycemia causes enhanced glucose metabolism by the polyol pathway in tissues not requiring insulin for glucose uptake. It…